Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04527991 · ClinicalTrials.gov registry record · Phase 3
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 711
- Enrollment target
NCT04527991 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 711 participants.
The verdict
NCT04527991, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 711 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).
Interventions
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Sacituzumab Govitecan-hziy
- DRUG Vinflunine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 711 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2025-07-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04527991
The ClinicalTrials.gov registry entry for NCT04527991 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 711 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT04527991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04527991 about?
NCT04527991 is a clinical study titled "Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread". The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).
What is the current status of trial NCT04527991?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 711 participants. The study started on 2021-01-13. Estimated completion is 2025-07-04.
What interventions are being tested in trial NCT04527991?
The interventions under investigation include: Docetaxel (DRUG), Paclitaxel (DRUG), Sacituzumab Govitecan-hziy (DRUG), Vinflunine (DRUG).
Who is sponsoring clinical trial NCT04527991?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.